BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Advances Novel Formulation of Drug Candidate in Battle against Advanced Breast Cancer
Development of frozen formulation of Bria-IMT completed for on-demand shipment to clinical sites Novel formulation is easily transportable to distant locations, easy to use, safe and has improved potency; it accommodates higher patient volumes at reduced per-dose costs Promising novel immunotherapy technology provides hope to patients with advanced breast cancer Breast cancer remains the leading cancer diagnosed in women and the second-most common cancer overall Immuno-oncology focused biotechnology company, BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) recently announced the imminent clinical use of a novel, frozen formulation of Bria-IMT, the company’s lead cancer drug candidate targeting the unmet medical needs…